KymaThera Raises $80M to Advance PI3Kα Cancer Drug
KymaThera has raised $80 million in a Series B financing to advance the development of its investigational cancer drug K-1728, an oral PI3Kα inhibitor designed to target multiple…
Read More...
Read More...
